TheraRadar
← Back
Data updated: Jun 28, 2026

INTRA SANA LABS

Generics
Pharmaceuticals

INTRA SANA LABS is a generic drug manufacturer with 2 FDA-approved products.

2008
Since
2
Drugs
-
Trials
0
New Drugs (2yr)

Upcoming FDA Decisions

Full Calendar →
Sep 19, 2026 — AQNEURSA (levacetylleucine)

INTRA SANA LABS's Key Drugs

INTRA SANA LABS's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

INTRA SANA LABS's Recent FDA Approvals

New NDA/BLA approvals for INTRA SANA LABS over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

INTRA SANA LABS's Therapeutic Areas

Disease areas where INTRA SANA LABS has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.

No indication data

INTRA SANA LABS Pipeline Snapshot

Active clinical trials for INTRA SANA LABS across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Top drug revenue breakdown
  • • Drug-level revenue analysis

Trial Catalysts

  • • Active trial monitoring
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling